Abstract 303P
Background
Mandibulectomy typically involves rigid reconstruction using autologous bone and titanium plates. However, in cases with poor performance status or complications as well as the elderly, choosing the optimal surgical method is difficult. For such cases in our hospital, we do not perform rigid reconstruction but opt for only soft tissue reconstruction or primary suturing at the defect site. Here, we retrospectively investigated cases where primary suturing was applied and discuss the utility of the procedure.
Methods
This retrospective study targeted cases of stage T4 lower gingival carcinoma treated with segmental mandibulectomy and primary suturing at the defect site between 1992 and 2018. Survey items were operative time, blood loss volume, perioperative complications, length of hospitalization, and food intake at discharge.
Results
There were 186 cases for which segmental mandibulectomy was performed during the target period, and 13 cases for which primary suturing was also performed. Median operative time was 210 (range, 124-328) min. Median blood loss was 212 (101-867) mL. Six cases had complications during the perioperative period, but in all cases cure was achieved by conservative treatment. Median length of hospitalization was 32 (20-49) days. All cases could tolerate oral intake at discharge.
Conclusions
Segmental mandibulectomy without reconstruction may be a viable surgical option for cases where free tissue reconstruction is not possible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract